Abstract

Epithelial ovarian cancer (EOC) is the gynecological malignancy with the highest death rate, characterized by frequent relapse and onset of drug resistance. Disease diagnosis and therapeutic follow-up could benefit from application of molecular imaging approaches, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), able to monitor metabolic and functional alterations and investigate the underlying molecular mechanisms. Here, we overview the quantitative alterations that occur during either orthotopic or subcutaneous growth of preclinical EOC models. A common feature of 1H MR spectra is the presence of a prominent peak due to total choline-containing metabolites (tCho), together with other metabolic alterations and MRI-detected morphofunctional patterns specific for different phenotypes. The tCho signal, already present at early stages of tumor growth, and changes of diffusion-weighted MRI parameters could serve as markers of malignancy and/or tumor response to therapy. The identification by MRS and MRI of biochemical and physiopathological fingerprints of EOC disease in preclinical models can represent a basis for further developments of non-invasive MR approaches in the clinical setting.

Highlights

  • Epithelial ovarian cancer (EOC) is the fifth cause of cancer-related deaths among women [1], leading to about 140,000 deaths worldwide per year

  • According to high resolution 1H magnetic resonance spectroscopy (MRS) analyses of cancer cell [23] and tissue extracts [21, 24], the total choline-containing metabolites (tCho) peak mainly comprises contributions from phosphocholine (PCho), glycerophosphocholine (GPCho), and free choline (Cho). These analyses showed that the PCho/tCho ratio in all cells used for implants shown in Figure 1 was greater than 0.70 [21, 24]

  • The in vivo tCho reduction was associated with increases in the T2 and apparent diffusion coefficient (ADC) mean values, along with reduced Ki67 index and HER2 content, suggesting that phosphatidylcholine-specific phospholipase C (PC-PLC) plays an important role in HER2-driven EOC cell signaling and tumorigenicity [36]

Read more

Summary

INTRODUCTION

Epithelial ovarian cancer (EOC) is the fifth cause of cancer-related deaths among women [1], leading to about 140,000 deaths worldwide per year. All these EOC models were examined between 26 and 50 days post implantation (dpi). The in vivo tCho reduction was associated with increases in the T2 and ADC mean values, along with reduced Ki67 index and HER2 content, suggesting that PC-PLC plays an important role in HER2-driven EOC cell signaling and tumorigenicity [36]

ITS POTENTIAL EFFECTS ON CANCER
FUTURE PROSPECTIVES WITH RADIOLABELED COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call